Tokyo Tape
Sign in
← Chiome Bioscience

Annual report

4583.TEDINET S100QGF6
Period2022-01-01 → 2022-12-31
Filed2023-03-28
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
MetricValuePeriodScopeSource row
Revenue¥631m2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥713m2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥481m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥448m2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥213m2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.3bn2022-01-01 → 2022-12-31StandaloneOperating income
Operating income−¥1.3bn2021-01-01 → 2021-12-31StandaloneOperating income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income−¥1.3bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.4bn2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.5bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.2bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Profit before tax−¥1.5bn2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Net income−¥1.2bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥1.5bn2021-01-01 → 2021-12-31StandaloneProfit loss
Net income−¥1.3bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.4bn2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.5bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥2.2bnat 2022-12-31StandaloneAssets
Total assets¥2.3bnat 2021-12-31StandaloneAssets
Total assets¥3.5bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.8bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.8bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥425mat 2022-12-31StandaloneLiabilities
Total liabilities¥446mat 2021-12-31StandaloneLiabilities
Net assets / equity¥1.8bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.9bnat 2021-12-31StandaloneNet assets
Net assets / equity¥3.1bnat 2020-12-31dStandaloneNet assets
Net assets / equity¥2.6bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥2.7bnat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.7bnat 2022-12-31StandaloneCash and deposits
Cash and deposits¥1.8bnat 2021-12-31StandaloneCash and deposits
Cash & equivalents¥1.7bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2021-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.7bnat 2020-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥2.3bnat 2018-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.2bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2021-01-01 → 2021-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.5bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.7bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥35m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥4m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥26m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.1bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥271m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.9bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.3bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥10m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.062020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-44.612019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-57.262018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥36.7at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥45.55at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥77.99at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥78.1at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥98.89at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio80.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio88.2%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio92.6%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio93.5%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued48,423,500at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued39,505,200at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued33,283,500at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued26,781,500at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees49at 2022-12-31StandaloneNumber of employees
Employees49at 2021-12-31StandaloneNumber of employees
Employees42at 2020-12-31dStandaloneNumber of employees
Employees38at 2019-12-31dStandaloneNumber of employees
Employees37at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 21
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥2.2bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-12-31−¥472m
Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-12-31−¥1.1bn
Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-12-31¥631m
Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-12-31¥631m
Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-12-31¥349m
—segment totalemployeesat 2022-12-3139 pure
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-12-31¥631m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-12-31¥631m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-12-31−¥787m
Reconciling Itemsreconcilingsegment assetsat 2021-12-31¥2.3bn
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-12-31−¥445m
Drug Discovery And Developmentreportable segmentrevenue2021-01-01 → 2021-12-31¥103m
Drug Discovery And Developmentreportable segmentrevenue external2021-01-01 → 2021-12-31¥103m
Drug Discovery And Developmentreportable segmentsegment profit2021-01-01 → 2021-12-31−¥1.2bn
Drug Discovery Supportreportable segmentrevenue2021-01-01 → 2021-12-31¥610m
Drug Discovery Supportreportable segmentrevenue external2021-01-01 → 2021-12-31¥610m
Drug Discovery Supportreportable segmentsegment profit2021-01-01 → 2021-12-31¥320m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-12-31¥713m
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-12-31¥713m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-12-31−¥890m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 834
ItemContextValueUnit
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoverySupportReportableSegmentsMember630815000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember630815000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember630815000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember-1135613000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoverySupportReportableSegmentsMember348858000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember-786755000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember-471899000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember-1258655000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E26096-000DrugDiscoverySupportReportableSegmentsMember－JPY
AssetsCurrentYearInstant_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
AssetsCurrentYearInstant_NonConsolidatedMember_ReconcilingItemsMember2215470000JPY
AssetsCurrentYearInstant_NonConsolidatedMember2215470000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-03-28
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第19期（自　2022年１月１日　至　2022年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社カイオム・バイオサイエンス
Company name in english cover pageFilingDateInstantChiome Bioscience Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　小林　茂
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都渋谷区本町三丁目12番１号
Telephone number address of registered headquarter cover pageFilingDateInstant03-6383-3746
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役経営企画室長　美女平　在彦
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都渋谷区本町三丁目12番１号
Telephone number nearest place of contact cover pageFilingDateInstant03-6383-3746
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役経営企画室長　美女平　在彦
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE26096
Fund codeFilingDateInstant－
Security codeFilingDateInstant45830
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社カイオム・バイオサイエンス
Filer name in englishFilingDateInstantChiome Bioscience Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Current fiscal year start dateFilingDateInstant2022-01-01
Current period end dateFilingDateInstant2022-12-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2022-12-31
Previous fiscal year start dateFilingDateInstant2021-01-01

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · operating cash flownon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass